DefinePK

Abstract

Background and Objectives: Ezetimibe/simvastatin and rosuvastatin drugs are two effective lipid-lowering therapies for hypercholesterolemic patients. However, whether the effect of ezetimibe/simvastatin is superior to rosuvastatin is is still controversial. Therefore, the purpose of this study was to compare the efficacy between ezetimibe/simvastatin and rosuvastatin for hypercholesterolemia treatment by a meta-analysis. Materials and Methods: Based on the predefined searching strategy and selection criteria, the eligible studies were selected. The quality of included study was evaluated using Cochrane Collaboration&#146s tool. The out come assessments indexes including low-density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterin (HDL-C), total cholesterin (Total C), triglycerides (TG) and apolipoprotein B (Apo B) were analyzed. In addition, the sub-group analysis was performed for comparing the efficacy of two groups with different dosages and sensitivity analysis was performed. Results: Totally, six studies were collected in the present study. The quality of the included studies were relatively high. Ezetimibe/simvastatin might result in greater LDL-C, Total C, TG and Apo B reductions than rosuvastatin for hypercholesterolemia. In addition, compared with 10 mg/day rosuvastatin, 10/20 mg/day ezetimibe/simvastatin had a better clinical efficacy in lipid-lowering of LDL-C, Total C, TG and Apo B. Moreover, no obvious changes of lipid-altering were observed between the rosuvastatin 40 mg/day and ezetimibe/simvastatin 10/40 mg/day. Conclusion: Ezetimibe/simvastatin was recommended to administrate hypercholesterolemia for providing greater reductions of LDL-C, Total C, TG and Apo B than rosuvastatin. Ezetimibe/simvastatin 10/20 mg/day had a better clinical efficacy than rosuvastatin 10 mg/day, while ezetimibe/simvastatin 10/40 mg/day had the same lipid-lowering than rosuvastatin 40 mg/day.